Condition: Phenylketonuria · Sponsor: BioMarin Pharmaceutical
Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.
This description comes directly from the study's public registry record.
Trial Specialist · 1-800-983-4587 · medinfo@bmrn.com
Always discuss trial participation with your own doctor first.
| UCLA Dept. of Human Genetics | Los Angeles, California, United States | Not Yet Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Not Yet Recruiting |
| University Of South Florida Medical Center | Tampa, Florida, United States | Not Yet Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Not Yet Recruiting |
| Indiana University School of Medicine | Indianapolis, Indiana, United States | Not Yet Recruiting |
| University of Minnesota Medical School | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| University of Rochester Medical Center (URMC) | Rochester, New York, United States | Not Yet Recruiting |
| Oregon Health & Science University (OHSU) - PARENT | Portland, Oregon, United States | Not Yet Recruiting |
| University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| University of Utah Hospital | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Children's Hospital of Wisconsin | Milwaukee, Wisconsin, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07477691